Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0011847
Disease: Diabetes
Diabetes 		0.050 GeneticVariation disease BEFREE Because mutations in human SHP1 underlie obesity and diabetes, SHP1 is a candidate gene for human lipodystrophy syndromes. 12181644 2002
CUI: C0023418
Disease: leukemia
leukemia 		0.050 Biomarker disease BEFREE These results suggest that functional loss of SHP1 is associated with the pathogenesis of leukemias/lymphomas. 12438221 2002
CUI: C0023418
Disease: leukemia
leukemia 		0.050 Biomarker disease LHGDN These results suggest that functional loss of SHP1 is associated with the pathogenesis of leukemias/lymphomas. 12438221 2002
CUI: C0024299
Disease: Lymphoma
Lymphoma 		0.050 Biomarker group BEFREE These results suggest that functional loss of SHP1 is associated with the pathogenesis of leukemias/lymphomas. 12438221 2002
CUI: C0024299
Disease: Lymphoma
Lymphoma 		0.050 Biomarker group LHGDN These results suggest that functional loss of SHP1 is associated with the pathogenesis of leukemias/lymphomas. 12438221 2002
CUI: C0023449
Disease: Acute lymphocytic leukemia
Acute lymphocytic leukemia 		0.030 Biomarker disease BEFREE Loss of heterozygosity with microsatellite markers near the SHP1 gene was shown in 79% of informative acute lymphoblastic leukemia cases. 12438221 2002
CUI: C0036920
Disease: Sezary Syndrome
Sezary Syndrome 		0.030 Biomarker disease LHGDN Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling. 12130517 2002
CUI: C0036920
Disease: Sezary Syndrome
Sezary Syndrome 		0.030 Biomarker disease BEFREE The standardization of a sensitive ELISA for the quantification of SHP-1 protein in peripheral T and B lymphocytes has enabled us to quantify the SHP-1 content of freshly isolated T cells from patients with Sezary syndrome and in the Sezary T cell line HUT-78. 12145687 2002
CUI: C0079773
Disease: Lymphoma, T-Cell, Cutaneous
Lymphoma, T-Cell, Cutaneous 		0.020 Biomarker disease LHGDN We demonstrate that ILT2 is functional on CTCL cells, as its triggering leads to the recruitment of Src homology 2 domain-containing tyrosine phosphatase (SHP-1) and to the specific inhibition of CTCL malignant cell proliferation induced by CD3/T-cell receptor (TCR) stimulation. 12130517 2002
CUI: C0023787
Disease: Lipodystrophy
Lipodystrophy 		0.010 GeneticVariation disease BEFREE The findings suggest that SHP1 mutations are not commonly seen in patients with lipodystrophy who had no mutations in known disease genes. 12181644 2002
CUI: C0028754
Disease: Obesity
Obesity 		0.010 GeneticVariation disease BEFREE Because mutations in human SHP1 underlie obesity and diabetes, SHP1 is a candidate gene for human lipodystrophy syndromes. 12181644 2002
CUI: C1961102
Disease: Precursor Cell Lymphoblastic Leukemia Lymphoma
Precursor Cell Lymphoblastic Leukemia Lymphoma 		0.010 Biomarker disease BEFREE Loss of heterozygosity with microsatellite markers near the SHP1 gene was shown in 79% of informative acute lymphoblastic leukemia cases. 12438221 2002
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.100 Biomarker group BEFREE SHP-1 protein tyrosine phosphatase has been implicated in suppressing B-lymphocyte and myeloid cell malignancies; however, there are little data on this role of SHP-1 in T-lymphocyte malignancies. 12591278 2003
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE These data support the possibility that the SHP1 gene is one of the tumor suppressor genes. 14691303 2003
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.100 Biomarker group BEFREE SHP-1 has been proposed as a candidate tumor suppressor gene in lymphoma, leukemia and other cancers, as it functions as an antagonist to the growth-promoting and oncogenic potentials of tyrosine kinase. 12657462 2003
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.070 AlteredExpression disease BEFREE SHP-1 expression also is decreased in some breast cancer cell lines with negative expression of estrogen receptor as well as some prostate and colorectal cancer cell lines. 12657462 2003
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.070 AlteredExpression disease BEFREE SHP-1 expression also is decreased in some breast cancer cell lines with negative expression of estrogen receptor as well as some prostate and colorectal cancer cell lines. 12657462 2003
CUI: C0023418
Disease: leukemia
leukemia 		0.050 Biomarker disease LHGDN The extraordinarily high frequency (75 to 100%) of CpG methylation of the SHP1 gene in B-cell lymphoma/leukemia patient specimens indicates that the SHP1 gene silencing is one of the critical events to the onset of malignant lymphomas/leukemias as well as important implications for the diagnostic or prognostic markers and the target of gene therapy. 14691303 2003
CUI: C0023418
Disease: leukemia
leukemia 		0.050 AlteredExpression disease BEFREE Previously we showed reduced protein and mRNA expression of the SHP1 gene in lymphoma/leukemia cell lines and patient specimens by Northern blot, RT-PCR, Western blot, and immunohistochemical analyses. 14691303 2003
CUI: C0024299
Disease: Lymphoma
Lymphoma 		0.050 Biomarker group BEFREE The extraordinarily high frequency (75 to 100%) of CpG methylation of the SHP1 gene in B-cell lymphoma/leukemia patient specimens indicates that the SHP1 gene silencing is one of the critical events to the onset of malignant lymphomas/leukemias as well as important implications for the diagnostic or prognostic markers and the target of gene therapy. 14691303 2003
CUI: C0024299
Disease: Lymphoma
Lymphoma 		0.050 Biomarker group LHGDN The extraordinarily high frequency (75 to 100%) of CpG methylation of the SHP1 gene in B-cell lymphoma/leukemia patient specimens indicates that the SHP1 gene silencing is one of the critical events to the onset of malignant lymphomas/leukemias as well as important implications for the diagnostic or prognostic markers and the target of gene therapy. 14691303 2003
CUI: C0024299
Disease: Lymphoma
Lymphoma 		0.050 AlteredExpression group BEFREE In this paper, we summarize recent studies on the expression and regulation of SHP-1 protein and its pathological function in the development of lymphoma, leukemia and other cancers. 12657462 2003
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.040 Biomarker group BEFREE The extraordinarily high frequency (75 to 100%) of CpG methylation of the SHP1 gene in B-cell lymphoma/leukemia patient specimens indicates that the SHP1 gene silencing is one of the critical events to the onset of malignant lymphomas/leukemias as well as important implications for the diagnostic or prognostic markers and the target of gene therapy. 14691303 2003
CUI: C0079744
Disease: Diffuse Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma 		0.040 GeneticVariation disease BEFREE In this study, aberrant methylation in the SHP1 gene promoter was detected in many B-cell leukemia/lymphoma cell lines as well as in patient specimens, including diffuse large B-cell lymphoma (methylation frequency 93%), MALT lymphoma (82%), mantle cell lymphoma (75%), plasmacytoma (100%) and follicular lymphoma (96%) by methylation-specific PCR, bisulfite sequencing, and restriction enzyme-mediated PCR analyses. 14691303 2003
CUI: C1332206
Disease: Adult Lymphoma
Adult Lymphoma 		0.040 PosttranslationalModification disease BEFREE It suggests that the SHP1 gene silencing with aberrant CpG methylation relates to the lymphoma progression. 14691303 2003